Aveo Completes Enrollment in Phase II Renal Cell Carcinoma Trial
Posted on: Friday, 30 May 2008, 06:00 CDT
Aveo Pharmaceuticals has completed enrollment in its 200-patient Phase II clinical trial of AV-951 in patients with metastatic renal cell carcinoma.
This placebo-controlled, randomized discontinuation trial is assessing the safety and efficacy of once-daily, oral AV-951 in metastatic renal cell carcinoma patients naive to VEGF targeted therapy at more than 30 sites in Europe and India under a US investigational new drug filing.
In this Phase II trial, all patients receive 16 weeks of AV-951, after which time patients are evaluated for response, stable disease or progressive disease. Those patients who experience a partial or complete response remain on therapy; those patients who experience stable disease are randomized to receive 12 weeks of AV-951 or placebo in a double-blind fashion.
The primary endpoints of this trial are objective response rate after 16 weeks of treatment, percentage of patients who are progression free at 12 weeks following randomization (28 weeks after study entry), and safety.
Tuan Ha-Ngoc, president and CEO of Aveo, said: "Based on our promising, early data, we believe the unique triple VEGF receptor inhibition and tolerability positions AV-951 as a potential best-in-class anti-angiogenic agent."
Source: Datamonitor
Related Articles
- Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
- Florida is State With Highest Percentage of Untreated Patients With Chronic Obstructive Pulmonary Disease
- Gentium Announces the Data Safety Monitoring Board Review of the Phase III Trial of Defibrotide to Treat Patients With Severe Veno-Occlusive Disease
- ZIOPHARM Treats Patients in U.S. Phase I Trials of Oral Darinaparsin and Indibulin
- Amarillo Biosciences Announces Upcoming Clinical Trial of Oral Interferon Therapy for Chronic Cough in Patients With Chronic Obstructive Pulmonary Disease
- Pharmaxis Enrolls Patients for COPD Trial
- NRC+Picker Highlights Safe Medication Administration During National Patient Safety Week
- Genzyme Begins Trial of Myozyme(R) for Patients With Late-Onset Pompe Disease
- GlycoGenesys, Inc. Achieves Primary Objective in Phase I Trial in Advanced Solid Tumors Preliminary Response Data on 14 Patients Shows 11 Achieve Stable Disease
- GenVec Launches Phase IIB Trial in Patients With Severe Coronary Artery Disease
 |
 |
User Comments (0)
RSS Feeds